Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellulitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Cellulitis. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2013-001218-14 Sponsor Protocol Number: ME/2012/4078 Start Date*: 2013-07-08
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A double blind randomised control trial to measure the effect of the addition of clindamycin to flucloxacillin for the treatment of limb cellulitis
    Medical condition: Cellulitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10007882 Cellulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002146-10 Sponsor Protocol Number: Ematonco/divmalinf/2006.2 Start Date*: 2006-09-06
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Rescue therapy of tunnel/pocket infections of Hickman-Broviac/Port indwelling central venous catheters with antibiotic continuous infusion
    Medical condition: Patients with Hemato-oncologic disease or undergoing Hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    6.1 10007882 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023918-30 Sponsor Protocol Number: SOMA-001-2010 Start Date*: 2011-03-16
    Sponsor Name:SOCIETA' ITALO BRITANNICA L. MANETTI - H.ROBERTS & C. PER AZIONI
    Full Title: Pilot clinical study on the systemic bioavailability of l-thyroxine in healthy female volunteers after four weeks of topical treatment with a new formulation based on l-thyroxine
    Medical condition: treatment of localized fat, accompanied by cellulite
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10065339 Cellulite LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000381-36 Sponsor Protocol Number: 26083 Start Date*: 2006-04-26
    Sponsor Name:University of Nottingham
    Full Title: Randomised controlled trials to investigate whether prophylactic antibiotics can prevent further episodes of cellulitis (erysipelas) of the leg (PATCH I & PATCH II)
    Medical condition: Cellulitis of the leg
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002106-31 Sponsor Protocol Number: 44512 Start Date*: 2014-04-01
    Sponsor Name:Academic Medical Center
    Full Title: The DANCE study: Duration of ANtibiotic therapy for CEllulitis
    Medical condition: Cellulitis (Cellulitis is a common acute, spreading pyogenic inflammation of the skin (dermis) and subcutaneous tissue, usually complicating a wound, ulcer or dermatosis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003740-89 Sponsor Protocol Number: MR-Som-01-20 Start Date*: 2020-11-26
    Sponsor Name:SOCIETÀ ITALO BRITANNICA L. MANETTI - H. ROBERTS & C. PER AZIONI
    Full Title: A Phase IV, interventional, monocentric, not controlled study for the evaluation of new clinical and instrumental parameters on the efficacy of SOMATOLINE in the treatment of local adiposity and ce...
    Medical condition: local adiposity and cellulite
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10007882 Cellulitis PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021842-23 Sponsor Protocol Number: TT108 Start Date*: 2010-09-15
    Sponsor Name:University of Iceland
    Full Title: A randomized clinical trial of the effects of Tea tree essential oil on adult leg cellulitis of class II in the Eron/Dall classification system for cellulitis: Pilot study.
    Medical condition: Cellulitis of the lower leg of adult patients that have been admitted to Landspitali University Hospital and are on iv antibiotics.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006151-42 Sponsor Protocol Number: 0 Start Date*: 2009-12-17
    Sponsor Name:Beaumont Hospital
    Full Title: A comparison of oral flucloxacillin alone with combined oral phenoxymethylpenicillin and flucloxacillin for the treatment of uncomplicated skin and soft tissue infections
    Medical condition: Infection of the skin and subcutaneous tissues (cellulitis)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007882 Cellulitis LLT
    9.1 10015145 Erysipelas LLT
    9.1 10021531 Impetigo LLT
    9.1 10000269 Abscess LLT
    9.1 10048038 Wound infection LLT
    9.1 10016936 Folliculitis LLT
    9.1 10017557 Furunculosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004539-57 Sponsor Protocol Number: Dio/01/2013 Start Date*: 2014-01-30
    Sponsor Name:ALIO MEDICA Sp. z o.o.
    Full Title: A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleang...
    Medical condition: lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10065339 Cellulite LLT
    17.0 100000004858 10043193 Telangiectasis LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021424-94 Sponsor Protocol Number: TMC-ORI-10-01 Start Date*: 2012-03-16
    Sponsor Name:The Medicines Company
    Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin...
    Medical condition: Treatment of Patients with acute bacterial skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10065240 Wound infection bacterial PT
    14.0 10021881 - Infections and infestations 10040872 Skin infection PT
    14.0 10021881 - Infections and infestations 10042343 Subcutaneous abscess PT
    14.0 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    14.0 10021881 - Infections and infestations 10007882 Cellulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021720-10 Sponsor Protocol Number: TMC-ORI-10-02 Start Date*: 2012-03-16
    Sponsor Name:The Medicines Company
    Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin...
    Medical condition: Treatment of Patients with acute bacterial skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10065240 Wound infection bacterial PT
    14.1 10021881 - Infections and infestations 10040872 Skin infection PT
    14.1 10021881 - Infections and infestations 10042343 Subcutaneous abscess PT
    14.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    14.1 10021881 - Infections and infestations 10007882 Cellulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001528-69 Sponsor Protocol Number: EmergencyMedicineTrial001 Start Date*: 2016-10-07
    Sponsor Name:Royal College of Surgeons in Ireland
    Full Title: PENICILLIN FOR THE EMERGENCY DEPARTMENT-DIRECTED OUTPATIENT TREATMENT OF CELLULITIS (PEDOCELL) STUDY: A NON-INFERIORITY ADAPTIVE RANDOMISED CONTROLLED TRIAL.
    Medical condition: Skin Infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003556-20 Sponsor Protocol Number: RH4131-03 Start Date*: 2014-02-19
    Sponsor Name:Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet
    Full Title: Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
    Medical condition: Necrotizing Soft Tissue Infections
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10055648 Necrotizing fasciitis fungal LLT
    16.1 10021881 - Infections and infestations 10052892 Necrotising fasciitis fungal PT
    16.1 10021881 - Infections and infestations 10055647 Necrotizing fasciitis LLT
    16.1 10021881 - Infections and infestations 10055649 Necrotizing fasciitis staphylococcal LLT
    16.1 10021881 - Infections and infestations 10017068 Fournier's gangrene LLT
    16.1 10021881 - Infections and infestations 10028885 Necrotising fasciitis PT
    16.1 10021881 - Infections and infestations 10016229 Fasciitis necrotising LLT
    16.1 10021881 - Infections and infestations 10028886 Necrotising fasciitis NOS LLT
    16.1 10021881 - Infections and infestations 10028888 Necrotising fasciitis streptococcal PT
    16.1 10021881 - Infections and infestations 10028887 Necrotising fasciitis staphylococcal PT
    16.1 10021881 - Infections and infestations 10055650 Necrotizing fasciitis streptococcal LLT
    16.1 10021881 - Infections and infestations 10055643 Fasciitis necrotizing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003812-22 Sponsor Protocol Number: P903-23 Start Date*: 2011-10-31
    Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories)
    Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA LT (Completed) LV (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005283-47 Sponsor Protocol Number: P903-07 Start Date*: 2006-12-29
    Sponsor Name:Cerexa, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and ...
    Medical condition: Complicated Skin and Skin Structure Infections (cSSSI)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052891 Skin bacterial infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-024042-30 Sponsor Protocol Number: DUR001-301 Start Date*: 2012-05-04
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKI...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002130-40 Sponsor Protocol Number: DUR001-302 Start Date*: 2011-11-23
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SK...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000419-15 Sponsor Protocol Number: DUR001-303 Start Date*: 2014-07-28
    Sponsor Name:Durata Therapeutics International B.V.
    Full Title: A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin ...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001125-15 Sponsor Protocol Number: ATB-202 Start Date*: 2018-07-16
    Sponsor Name:Atox Bio
    Full Title: Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI)
    Medical condition: Necrosis of soft tissue infections (NSTI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10065769 Soft tissue necrosis PT
    20.0 10021881 - Infections and infestations 10017068 Fournier's gangrene LLT
    20.1 10021881 - Infections and infestations 10028885 Necrotising fasciitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA